BioCentury | Jul 9, 2020
Finance

Ascendis leads latest pack of follow-ons with $600M raise

...7.1 million shares at $42, a slight 2% premium to its Monday close of $41.02 Akero Therapeutics Inc....
...significant fund flows to the sector (see “May's Momentum Continues” ). Virginia Li, Associate Editor Ascendis Pharma A/S Akero Therapeutics Inc. 89bio...
BioCentury | Jul 6, 2020
Product Development

NASH ups and downs, COVID-19 vaccines & real-world data for diagnostics: a BioCentury podcast

...Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), and what that decision means for other NASH therapy developers including Akero Therapeutics Inc....
...serology tests for COVID-19 (see “Accelerating the Fight Against COVID-19” ). BC Staff Pfizer Inc. BioNTech AG Intercept Pharmaceuticals Inc. Akero Therapeutics Inc. covid-19 cov19pol cov19count cov19pol cov19count...
BioCentury | Jul 1, 2020
Product Development

Histology data builds on growing confidence around Akero’s NASH candidate

...to approve what would have been the first drug for the indication earlier this week. Akero Therapeutics Inc....
...Targets FGF21 - Fibroblast growth factor 21 FXR (NR1H4) - Farnesoid X receptor Lauren Martz, Senior Editor AKR-001 Akero Therapeutics Inc. Intercept...
BioCentury | Jun 5, 2020
Finance

In age of megafunds, Atlas stays the course with $400M twelfth venture fund

...area or company format.” Michael Gladstone, Atlas Among the listed companies are liver disease company Akero Therapeutics Inc....
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...at the share price, it wasn’t reflecting the positive Phase III readout.” Similarly, NASH play Akero Therapeutics Inc....
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...trended more towards IPOs, he said, because it was a hotter market at the time. Akero Therapeutics Inc....
...has promoted Richard Gaster to partner. Targets CGRP - Calcitonin gene-related peptide Elizabeth S. Eaton, Staff Writer Akero Therapeutics Inc. covid-19...
BioCentury | Apr 1, 2020
Product Development

Akero reports positive Phase IIa data for NASH; pandemic delays expansion cohort

...FGFR1, FGFR2 and FGFR3. AKR-001’s effect on fibrosis will not become clear until 2Q20, when Akero Therapeutics Inc....
...factor (FGF) receptor 2 FGFR3 (CD333) - Fibroblast growth factor (FGF) receptor 3 Hongjiang Li, Staff Writer AKR-001 Akero Therapeutics Inc. Fibroblast...
BioCentury | Dec 5, 2019
Finance

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

...billion in its open-ended Fund IV, launched in 2012; its portfolio includes liver disease company Akero Therapeutics Inc....
BioCentury | Oct 7, 2019
Company News

Gilead fills CMO spot with Genentech exec Parsey

...succeed Andrew Cheng, who stepped down as CMO in September 2018 to join NASH company Akero Therapeutics Inc....
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...named Andrew Cheng to the company's board of directors. He is president and CEO at Akero Therapeutics Inc....
Items per page:
1 - 10 of 25
BioCentury | Jul 9, 2020
Finance

Ascendis leads latest pack of follow-ons with $600M raise

...7.1 million shares at $42, a slight 2% premium to its Monday close of $41.02 Akero Therapeutics Inc....
...significant fund flows to the sector (see “May's Momentum Continues” ). Virginia Li, Associate Editor Ascendis Pharma A/S Akero Therapeutics Inc. 89bio...
BioCentury | Jul 6, 2020
Product Development

NASH ups and downs, COVID-19 vaccines & real-world data for diagnostics: a BioCentury podcast

...Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), and what that decision means for other NASH therapy developers including Akero Therapeutics Inc....
...serology tests for COVID-19 (see “Accelerating the Fight Against COVID-19” ). BC Staff Pfizer Inc. BioNTech AG Intercept Pharmaceuticals Inc. Akero Therapeutics Inc. covid-19 cov19pol cov19count cov19pol cov19count...
BioCentury | Jul 1, 2020
Product Development

Histology data builds on growing confidence around Akero’s NASH candidate

...to approve what would have been the first drug for the indication earlier this week. Akero Therapeutics Inc....
...Targets FGF21 - Fibroblast growth factor 21 FXR (NR1H4) - Farnesoid X receptor Lauren Martz, Senior Editor AKR-001 Akero Therapeutics Inc. Intercept...
BioCentury | Jun 5, 2020
Finance

In age of megafunds, Atlas stays the course with $400M twelfth venture fund

...area or company format.” Michael Gladstone, Atlas Among the listed companies are liver disease company Akero Therapeutics Inc....
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...at the share price, it wasn’t reflecting the positive Phase III readout.” Similarly, NASH play Akero Therapeutics Inc....
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

...trended more towards IPOs, he said, because it was a hotter market at the time. Akero Therapeutics Inc....
...has promoted Richard Gaster to partner. Targets CGRP - Calcitonin gene-related peptide Elizabeth S. Eaton, Staff Writer Akero Therapeutics Inc. covid-19...
BioCentury | Apr 1, 2020
Product Development

Akero reports positive Phase IIa data for NASH; pandemic delays expansion cohort

...FGFR1, FGFR2 and FGFR3. AKR-001’s effect on fibrosis will not become clear until 2Q20, when Akero Therapeutics Inc....
...factor (FGF) receptor 2 FGFR3 (CD333) - Fibroblast growth factor (FGF) receptor 3 Hongjiang Li, Staff Writer AKR-001 Akero Therapeutics Inc. Fibroblast...
BioCentury | Dec 5, 2019
Finance

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

...billion in its open-ended Fund IV, launched in 2012; its portfolio includes liver disease company Akero Therapeutics Inc....
BioCentury | Oct 7, 2019
Company News

Gilead fills CMO spot with Genentech exec Parsey

...succeed Andrew Cheng, who stepped down as CMO in September 2018 to join NASH company Akero Therapeutics Inc....
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...named Andrew Cheng to the company's board of directors. He is president and CEO at Akero Therapeutics Inc....
Items per page:
1 - 10 of 25